Thymic epithelial cell (TEC)

Thymic epithelial cells (TECs) are the primary non-hematopoietic stromal components of the thymus, essential for the development and selection of a functional and self-tolerant T-cell repertoire (NIH, 2022). They are broadly categorized into cortical TECs (cTECs), which mediate positive selection of thymocytes, and medullary TECs (mTECs), which are responsible for negative selection and the induction of central tolerance through the expression of the autoimmune regulator (AIRE) (Wikipedia, 2022; MDPI, 2022). These cells provide critical signals for T-cell lineage commitment, proliferation, and maturation through the expression of ligands such as DLL4 and chemokines like CXCL12 and CCL25 (Elsevier, 2022). Dysfunction or neoplastic transformation of TECs leads to various pathologies, including thymic epithelial tumors (TETs) such as thymomas and thymic carcinomas, as well as autoimmune disorders like myasthenia gravis (Frontiers, 2022; Cornell, 2022). While TECs themselves are a cell type rather than a single molecular target, they express several proteins that are therapeutic targets in oncology and immunology, such as XPO1, TROP2, and various immune checkpoint molecules (AACR Journals, 2021; Oncodaily, 2024). Current therapeutic strategies involving TECs range from chemotherapy and targeted inhibitors for malignancies to experimental approaches aimed at thymic regeneration and T-cell reconstitution (Drug Target Review, 2024; NIH, 2013). Safety concerns associated with targeting TEC-related pathways include the risk of severe autoimmune toxicity and the potential for impaired immune surveillance (NIH, 2022).

Other names

Epithelioreticular cellThymic epitheliumCortical thymic epithelial cell (cTEC)Medullary thymic epithelial cell (mTEC)Thymic nurse cellHassall's corpuscle epithelial cell

XPO1 inhibition, TROP2-directed antibody-drug conjugate, PD-1 inhibition, DNA alkylation, Topoisomerase II inhibition, Platinum-based DNA cross-linking, Glucocorticoid receptor agonism, mTOR inhibition, VEGFR inhibition